MYX 4.56% $4.82 mayne pharma group limited

General Discussion Topics, page-288

  1. 981 Posts.
    lightbulb Created with Sketch. 153
    I expect most, if not all, of the non-cash impairments from the generics business have already been disclosed. Looks like they cleared the decks in the half yearly. The impairments recognised in the first half will of course flow through to the FY21 but it's not like they will come as a surprise to the market.
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.